cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.. Lancet. 2016; 387 (10030): 1817-26.
92.Calverley PMA, Anderson AMA, Ferguson GT et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–89.
93.Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699–708.
94.Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD003794.
95.Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68: 1029–36.
96.Janson C, Larsson K, Lisspers KH, St€allberg B, Stratelis G, Goike H et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroids and long acting b2 agonist: observational matched cohort study (PATHOS). Br Med J 2013;346: f3306.
97.Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;Art. No.:CD010115.
98.Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001–6.
99.Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;5:CD002309.
100.Calverley PMA, Rabe KF, Goehring U-M et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685–94.
101.Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;3:CD005374.
102.Schols AMWJ, Wesseling G, Kester ADM et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17:337–42.
103.Man WD-C, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin Sci (Lond) 2009;117:251–64.
104.Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013;188:901–6.
56
105.Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S et al. Positive benefits of theophylline in a randomized, double-blind, parallelgroup, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006;11:603–10.
106.Ram FS, Jones P, Jardim J, Castro AA, Atallah AN, Lacasse Y et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;3:CD003902.
107.Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058–69.
108.Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A metaanalysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med 2013;107:1385–92.
109.Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689–98.
110.Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;8:CD001287.
111.Cazzola M, Calzetta L, Page C et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis // Eur Respir Rev 2015; 24(137): 451-61.
112.Al-Showair RA, Tarsin WY, Assi KH et al Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? // Respir Med 2007;101:2395-401.
113.Laube BL, Janssens HM, de Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308–31.
114.Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75:18–25.
115.Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev 2005;14:117–22.
116.Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;1:CD002733.
117.Sestini P, Renzoni E, Robinson S et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease // Cochrane database Syst Rev 2002; (4):
CD001495
57
118.Appleton S, Poole P, Smith B et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease // Cochrane database of systematic reviews 2006; 3(3): CD001104
119.Barr RG, Bourbeau J, Camargo CA et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease // Cochrane database of systematic reviews 2005;(2): CD002876
120.Van der Molen T, Cazzola M Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes // Primary Care Respir J 2012; 21(1): 101-8.
121.Mahler DA, Decramer M, D`Urzo A et al.Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study Eur Respir J 2014; 43(6): 1599-609.
122.Wedzicha JA, Banerji D, Chapman KR et al.; FLAME Investigators.. IndacaterolGlycopyrronium versus Salmeterol-Fluticasone for COPD // N Engl J Med. 2016; 374 (23): 2222-34.
123.Pascoe S, Locantore N, Dransfield M et al. Blood eosinophil counts, exacerbations and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials // Lancet Respir Med 2015 Jun 3 (6): 435-42.
124.Singh D, Brooks J, Hagan G et al. Superiority of «triple» therapy with
salmeterol/fluticasone propionate and tiotropium bromide |
versus individual |
components in moderate to severe COPD // Thorax 2008; 63 (7): 592-8.
125.Singh D, Papi A, Corradi M et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled tria // Lancet 2016; 388 (10048): 963-73.
126.Calverley PM, Marrtinez FJ, Fabbri LM et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol // Int J Chron Obstruct Pulmon Dis 2012 Vol 7 P. 375-382.
127.White P, Thorntoh H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS ONE 2013;8:e75221.
58
128.Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO) // Respir Res. 2014;15: 77.
129.Magnussen H, Disse B, Rodriguez-Roisin R et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD // N Engl J Med 2014;371:1285–94.
130.Naunheim KS, Wood DE, Mohsenifar Z et al. Long-term follow-up of patients receiving lung-volume reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group // Ann Thorac Surg 2006; 82: 431-43.
131.Orens JB, Estenne M, Arcasoy S et al.Internationalguidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745-55.
132.Stoller JK, Panos RJ, Krachman S. et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial // Chest 2010; 138:179-87.
133.Moore RP, Berlowitz DJ, Denehy L. et al. A randomized trial of domiciliary, ambulatory oxygen tin patients with COPD and dyspnea but without resting hypoxaemia // Thorax 2011;66:32-7.
134.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease // Am J Respir Crit Care Med 1995; 152: S77S120
135.Murphy PB, Rehal S, Arbane G et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomised clinical trial. JAMA. 2017;317:2177-86
136.Kohnlein T, Windish W, Kohler D et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicenter, randomized controlled clinical trial // Lancet Respir Med 2014 Sep 2 (9): 698-705.
137.Lightowler JV, Wedzicha JA, Elliott MW et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis // BMJ 2003; 326 (7382): 185.
138.McEvoy RD, Pierce RJ , Hillman D et al. Nocturnal non-invasive nasal ventilation
in stable hypercapnic COPD: a randomised controlled trial // Thorax 2009:64:561-6. 59
139.Higgings BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991;4:415–20.
140.O’Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992;86:317–25.
141.Davies L, Angus RM, Calverley PM Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial // Lancet 1999; 354 (9177): 456-60.
142.Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial // Am J Respir Crit Care Med 2002: 165(5): 698-703
143.Bafadhel M, McKenna S, Terry S et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial // Am J Respir Crit Care Med 2012; 186 (1): 48-55.
144.Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease // Ann Intern Med 1987; 106 (2): 196-204.
145.Miravitlles M, Kruesmann F, Haverstock D et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis // Eur Respir J 2012; 39(6): 135460.
146.Nouira S, Marghli S, Belghith M et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial // Lancet 2001; 358 (9298): 2020-5.
147.Weis N, Almdal T C-reactive protein – can it be used as a marker of infection in patients with exacerbationof chronic obstructive pulmonary disease // Eur J Intern Med 2006; 17: 88-91
148.Dev D, Sankaran EWR, Cunnife J et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease // Respir Med 1998; 92: 664667.
149.Adams S, Luther M. Antibiotics are associated with lower relapse rates in outpatientswith acute exacerbations of chronic obstructive pulmonary disease // Chest 2000; 117: 1345-52.
150.Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between
bacterial flora in sputum and functional impairment in patients with acute 60